Status:
COMPLETED
ABCSG 8 - Adjuvant Treatment in Patients With Hormone Receptor-positive Breast Cancer With Good to Moderate Differentiation.
Lead Sponsor:
AstraZeneca
Conditions:
Breast Cancer
Eligibility:
FEMALE
Up to 80 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to assess the difference in event-free survival between postmenopausal women with hormone receptor-positive early breast cancer who switched from tamoxifen to anastrozole ...
Eligibility Criteria
Inclusion
- Invasive mammary carcinoma after radical treatment, without prior chemo/hormone/radiation therapy.
- At least 6 lymph nodes examined.
- Good or intermediate tumour differentiation.
- \<6 weeks before start of adjuvant therapy.
- Oestrogen or Progesterone positive
Exclusion
- Premenopausal.
- Preoperative hormonal/antihormonal/radiation/cytoxic chemo. Second malignant tumour/status post second malignant tumour.
- In-situ/T4 carcinoma.
- Age \>80 years.
- World Health Organisation performance index \>3.
- Serious accompanying diseases
Key Trial Info
Start Date :
January 1 1996
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2009
Estimated Enrollment :
3858 Patients enrolled
Trial Details
Trial ID
NCT00291759
Start Date
January 1 1996
End Date
June 1 2009
Last Update
January 30 2013
Active Locations (52)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Amstetten, Austria
2
Research Site
Bad Ischl, Austria
3
Research Site
Baden, Austria
4
Research Site
Bregenz, Austria